COMMUNIQUÉS West-GlobeNewswire

Bronson Methodist Hospital Named No. 1 Academic Medical Center in the Nation; Earns Premier 100 Top Hospital® Honor
21/04/2026
KALAMAZOO, Mich., April 21, 2026 (GLOBE NEWSWIRE) -- Bronson Methodist Hospital is one of the nation’s 100 Top Hospitals® and the top Academic Medical Center in the U.S., according to an independent quality analysis [...]
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
21/04/2026
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
21/04/2026
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) MOGAD is a rare autoimmune disease of the central nervous system characterised [...]
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
21/04/2026
Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage [...]
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been [...]
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
21/04/2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company [...]
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
21/04/2026
· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study in the United States. Nes-Ziona, Israel, April 21, 2026 ( [...]
Brain Cancer Canada Marks Brain Cancer Awareness Month in May with National Landmark Lightings, Community Events, New Research Investments, and a Call to Action
21/04/2026
Awareness events Research grant awards Gala for Brain Cancer Research with Catherine Wreford and Dr. Cynthia Hawkins TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the only national charity [...]
AuX Labs Secures $4M to Commercialize Precision Fermentation Cheese Platform
21/04/2026
Funding will accelerate the launch of a scalable, precision-fermented dairy protein technology that performs like traditional cheese TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- AuX Labs, a food technology company using [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
21/04/2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
21/04/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established [...]
Celularity Announces Closing of Transaction with NexGel
21/04/2026
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously [...]
Twentyeight Health Launches First Nationwide All-in-One Virtual Clinic & Personalized Care for Women
21/04/2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Twentyeight Health, the leading provider-led digital-first women’s healthcare platform today announces the launch of Complete Care, an insurance-enabled membership model [...]
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
21/04/2026
Expansion Adds to Growing Global Trial Footprint Patient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), [...]
ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
21/04/2026
– Company to present updated data from the Phase 3 ENLIGHTED trial of Pa deliporfin VTP in LG UTUC with topline data expected in 2026 – – Additional preliminary data from the Phase 1 trial in LA-PDAC to be presented at [...]
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
21/04/2026
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics
21/04/2026
Research published in the Journal of Clinical Microbiology PORTOLA VALLEY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a national nonprofit and leading sponsor of tick-borne disease research in [...]
Milestone Scientific Inc. Completes $2.15 Million Private Placement
21/04/2026
Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board ROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific [...]
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
21/04/2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical [...]

Pages